ATOSSA THERAPEUTICS I

1,5000

08-ноября-24 15:59:57

15 мин. задержка

Акции

0,0000

0,00%

Сегодняшний диапазон

1,4500 - 1,5050

ISIN

N/A

Источник

NASDAQ

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

05 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

04 ноя 2024 06:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

31 окт 2024 08:15:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

21 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

14 окт 2024 17:08:43 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

01 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

10 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

28 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

21 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

20 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

12 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

22 июл 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

02 июл 2024 16:15:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

28 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Set to Join Russell 3000® Index Effective June 28, 2024

17 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa to Present at the Sidoti Small-Cap Investor Conference

05 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

28 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

15 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

13 май 2024 08:50:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.